Literature DB >> 9477094

Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.

M P Castro1.   

Abstract

BACKGROUND: Advanced carcinoma of the gallbladder typically is unresponsive to chemotherapy, and patients with progressive metastatic disease have a short survival.
METHODS: A patient with advanced metastatic carcinoma of the gallbladder causing peritoneal carcinomatosis and hepatic metastases is reported. This patient achieved a dramatic remission with gemcitabine after failing two other chemotherapeutic regimens.
RESULTS: Response included reversal of complete small bowel obstruction with resumption of the ability to eat and the disappearance of liver metastases.
CONCLUSIONS: Gemcitabine appears to be worthy of organized clinical trials in patients with this notoriously chemotherapy-resistant malignancy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477094     DOI: 10.1002/(sici)1097-0142(19980215)82:4<639::aid-cncr4>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.

Authors:  Syma Iqbal; Cathryn Rankin; Heinz-Josef Lenz; Philip J Gold; Syed A Ahmad; Anthony B El-Khoueiry; Michael J Messino; Randall F Holcombe; Charles D Blanke
Journal:  Cancer Chemother Pharmacol       Date:  2011-05-10       Impact factor: 3.333

2.  A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.

Authors:  Jae-Yong Cho; Ji-Sun Nam; Mi-Suk Park; Jeong-Sik Yu; Yong-Han Paik; Se-Joon Lee; Dong-Ki Lee; Dong-Sup Yoon
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

Review 3.  Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.

Authors:  Heng Liu; Qi-Di Zhang; Zheng-Hong Li; Qing-Qing Zhang; Lun-Gen Lu
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

4.  Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.

Authors:  Brian A Costello; Mitesh J Borad; Yingwei Qi; George P Kim; Donald W Northfelt; Charles Erlichman; Steven R Alberts
Journal:  Invest New Drugs       Date:  2014-04-18       Impact factor: 3.850

5.  Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.

Authors:  Steven R Alberts; Jonathan R Sande; Nathan R Foster; Fernando J Quevedo; Robert R McWilliams; John W Kugler; Tom R Fitch; Anthony J Jaslowski
Journal:  J Gastrointest Cancer       Date:  2008-11-21

Review 6.  Chemotherapy for the biliary tract cancers: moving toward improved survival time.

Authors:  Adriana Romiti; Chiara D'Antonio; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Viola Barucca; Valeria Durante; Paolo Marchetti
Journal:  J Gastrointest Cancer       Date:  2012-09

7.  Early relapse of unresectable gallbladder cancer after discontinuation of gemcitabine monotherapy administered for 5 years in a patient who had complete response to the treatment.

Authors:  Koichi Suyama; Masafumi Ikeda; Eiichiro Suzuki; Motohiro Kojima; Shuichi Mitsunaga; Satoshi Shimizu; Izumi Ohno; Hideaki Takahashi; Hiroyuki Okuyama; Akiko Kuwahara; Takuji Okusaka; Junji Furuse
Journal:  Case Rep Oncol       Date:  2013-10-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.